China's US M&A woes are only just warming up

The Trump administration is beginning to back up its beligerent words with action, and deals in the biotech and semiconductors sectors are at particular risk.

China's US M&A woes are only just warming up

When the tub-thumping campaign rhetoric of candidate Donald Trump was transformed, against all expectations, into a narrow election victory, there was little doubt that the path ahead for acquisitive Chinese conglomerates would be tougher.

Trump, it was speculated, would use the Committee on Foreign Investment in the United States, Cfius, to slow down Chinese dealmaking and indeed it has complicated the picture for Chinese buyers and seen deals withdrawn, delayed, or failed.


FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: us | china | donald trump | cfius | willbur ross | regulation

Print Edition

FinanceAsia Print Edition